Jim Cramer Urges AI Investors to Focus on Remaining Upside Not Past Gains Wall Street Mixed as Oil Prices Drop on Iran Deal Hopes Micron Jumps GlobalFoundries Tumbles Perpetua Resources Secures 29 Billion US Loan for Idaho GoldAntimony Project Elon Musk and Sam Altmans Rivalry Intensifies on Wall Street Ferraris Strategic Bet Luce FiveSeat EV Targets Generational Technology Shift Analyst Report Highlights Potential Growth Trajectory for Walmart Inc Amid Evolving Retail Landscape MATV Q1 2026 Earnings Massive EPS Surprise Drives Stock Higher Accuray ARAY Q1 2026 Earnings EPS Misses Estimates Stock Surges 22 on Strategic Progress HALO Q1 2026 Earnings EPS Beat Drives Modest Stock Uptick Espey Mfg Electronics Corp Q1 2026 Earnings EPS Surges Past Estimates with 114 Beat ALT Q1 2026 Earnings Strong EPS Beat Highlights Continued Pipeline Progress Enpro Inc NPO Q1 2026 Earnings EPS Beats Estimates Amid Modest Stock Gain Axcelis Technologies Edges Higher Amid Support Resistance Looms Barnwell Industries BRN Holds Steady at 108 as Consolidation Continues NewHold Investment Corp III Warrants NHICW Surge 1137 Testing Key Resistance at 093 LCI Industries LCII Holds Firm Near Support as Modest Gains Signal Potential Stability CNO Financial Group Holds Steady Near Support After Minor Pullback Intel Corporation INTC Among Most Traded US Stocks in 2026 as Analyst Lifts Price Target and McLaren Partnership Unfolds API Q4 2025 Earnings Profitability Emerges Amid Revenue Uncertainty ESAB Corporation ESAB Gains 294 as Technical Levels Come into Focus RBB Q1 2026 Earnings EPS Surges 438 Above Estimates Stock Edges Lower CC Q1 2026 Earnings Strong EPS Surprise Despite Unreported Revenue PSNY Q4 2024 Earnings WiderthanExpected Loss Amidst Operational Challenges Deutsche Bank Q1 2026 Earnings Modest EPS Beat Fails to Lift Stock Greenidge Generation Holdings Inc GREE Q1 2025 Earnings Narrowed Loss Beats Estimates as Bitcoin Mining Operations Adjust CTEV Q1 2026 Earnings Significant EPS Miss Amidst Operational Challenges INAB Q1 2026 Earnings NarrowerthanExpected Loss as Clinical Stage Company Advances Pipeline